Strides’ FDA Woes Continue
  • Prabha Hedge
  • Dec 05 2013

December 5: U.S. FDA worries may cost Strides Arcolabs dearly, as Mylan may hold back $250 million from its $1.75 billion deal to buy Strides' injectibles unit. Bloomberg TV India’s Agam Vakil shares a detailed report.